PBRM1 and neoplasm: Secondly, we showed a tumor response of tazemetostat in only one model harboring a PBRM1 variant (out of four models harboring mutations affecting SWI/SNF complexes), considering the slow-growth of the tumor in those PDX models, and we did not test the drug in non-PBRM1-mutated models.